Copyright Reports & Markets. All rights reserved.

Global Cancer Immunotherapies Sales Market Report 2021

Request for Sample of this report
Buy now

1 Cancer Immunotherapies Market Overview

  • 1.1 Cancer Immunotherapies Product Scope
  • 1.2 Cancer Immunotherapies Segment by Type
    • 1.2.1 Global Cancer Immunotherapies Sales by Type (2016 & 2021 & 2027)
    • 1.2.2 Monoclonal Antibodies (MABs)
    • 1.2.3 Cancer Vaccines
    • 1.2.4 Immunomodulators
    • 1.2.5 Adoptive Cell transfer
    • 1.2.6 Checkpoint Inhibitors
  • 1.3 Cancer Immunotherapies Segment by Application
    • 1.3.1 Global Cancer Immunotherapies Sales Comparison by Application (2016 & 2021 & 2027)
    • 1.3.2 Breast Cancer
    • 1.3.3 Leukemia
    • 1.3.4 Lymphoma
    • 1.3.5 Melanoma
    • 1.3.6 Colorectal Cancer
    • 1.3.7 Non-Small Cell Lung Cancer
  • 1.4 Cancer Immunotherapies Market Estimates and Forecasts (2016-2027)
    • 1.4.1 Global Cancer Immunotherapies Market Size in Value Growth Rate (2016-2027)
    • 1.4.2 Global Cancer Immunotherapies Market Size in Volume Growth Rate (2016-2027)
    • 1.4.3 Global Cancer Immunotherapies Price Trends (2016-2027)

2 Cancer Immunotherapies Estimates and Forecasts by Region

  • 2.1 Global Cancer Immunotherapies Market Size by Region: 2016 VS 2021 VS 2027
  • 2.2 Global Cancer Immunotherapies Retrospective Market Scenario by Region (2016-2021)
    • 2.2.1 Global Cancer Immunotherapies Sales Market Share by Region (2016-2021)
    • 2.2.2 Global Cancer Immunotherapies Revenue Market Share by Region (2016-2021)
  • 2.3 Global Cancer Immunotherapies Market Estimates and Forecasts by Region (2022-2027)
    • 2.3.1 Global Cancer Immunotherapies Sales Estimates and Forecasts by Region (2022-2027)
    • 2.3.2 Global Cancer Immunotherapies Revenue Forecast by Region (2022-2027)
  • 2.4 Geographic Market Analysis: Market Facts & Figures
    • 2.4.1 North America Cancer Immunotherapies Estimates and Projections (2016-2027)
    • 2.4.2 Europe Cancer Immunotherapies Estimates and Projections (2016-2027)
    • 2.4.3 China Cancer Immunotherapies Estimates and Projections (2016-2027)
    • 2.4.4 Japan Cancer Immunotherapies Estimates and Projections (2016-2027)
    • 2.4.5 Southeast Asia Cancer Immunotherapies Estimates and Projections (2016-2027)
    • 2.4.6 India Cancer Immunotherapies Estimates and Projections (2016-2027)

3 Global Cancer Immunotherapies Competition Landscape by Players

  • 3.1 Global Top Cancer Immunotherapies Players by Sales (2016-2021)
  • 3.2 Global Top Cancer Immunotherapies Players by Revenue (2016-2021)
  • 3.3 Global Cancer Immunotherapies Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Cancer Immunotherapies as of 2020)
  • 3.4 Global Cancer Immunotherapies Average Price by Company (2016-2021)
  • 3.5 Manufacturers Cancer Immunotherapies Manufacturing Sites, Area Served, Product Type
  • 3.6 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Global Cancer Immunotherapies Market Size by Type

  • 4.1 Global Cancer Immunotherapies Historic Market Review by Type (2016-2021)
    • 4.1.1 Global Cancer Immunotherapies Sales Market Share by Type (2016-2021)
    • 4.1.2 Global Cancer Immunotherapies Revenue Market Share by Type (2016-2021)
    • 4.1.3 Global Cancer Immunotherapies Price by Type (2016-2021)
  • 4.2 Global Cancer Immunotherapies Market Estimates and Forecasts by Type (2022-2027)
    • 4.2.1 Global Cancer Immunotherapies Sales Forecast by Type (2022-2027)
    • 4.2.2 Global Cancer Immunotherapies Revenue Forecast by Type (2022-2027)
    • 4.2.3 Global Cancer Immunotherapies Price Forecast by Type (2022-2027)

5 Global Cancer Immunotherapies Market Size by Application

  • 5.1 Global Cancer Immunotherapies Historic Market Review by Application (2016-2021)
    • 5.1.1 Global Cancer Immunotherapies Sales Market Share by Application (2016-2021)
    • 5.1.2 Global Cancer Immunotherapies Revenue Market Share by Application (2016-2021)
    • 5.1.3 Global Cancer Immunotherapies Price by Application (2016-2021)
  • 5.2 Global Cancer Immunotherapies Market Estimates and Forecasts by Application (2022-2027)
    • 5.2.1 Global Cancer Immunotherapies Sales Forecast by Application (2022-2027)
    • 5.2.2 Global Cancer Immunotherapies Revenue Forecast by Application (2022-2027)
    • 5.2.3 Global Cancer Immunotherapies Price Forecast by Application (2022-2027)

6 North America Cancer Immunotherapies Market Facts & Figures

  • 6.1 North America Cancer Immunotherapies Sales by Company
    • 6.1.1 North America Cancer Immunotherapies Sales by Company (2016-2021)
    • 6.1.2 North America Cancer Immunotherapies Revenue by Company (2016-2021)
  • 6.2 North America Cancer Immunotherapies Sales Breakdown by Type
    • 6.2.1 North America Cancer Immunotherapies Sales Breakdown by Type (2016-2021)
    • 6.2.2 North America Cancer Immunotherapies Sales Breakdown by Type (2022-2027)
  • 6.3 North America Cancer Immunotherapies Sales Breakdown by Application
    • 6.3.1 North America Cancer Immunotherapies Sales Breakdown by Application (2016-2021)
    • 6.3.2 North America Cancer Immunotherapies Sales Breakdown by Application (2022-2027)

7 Europe Cancer Immunotherapies Market Facts & Figures

  • 7.1 Europe Cancer Immunotherapies Sales by Company
    • 7.1.1 Europe Cancer Immunotherapies Sales by Company (2016-2021)
    • 7.1.2 Europe Cancer Immunotherapies Revenue by Company (2016-2021)
  • 7.2 Europe Cancer Immunotherapies Sales Breakdown by Type
    • 7.2.1 Europe Cancer Immunotherapies Sales Breakdown by Type (2016-2021)
    • 7.2.2 Europe Cancer Immunotherapies Sales Breakdown by Type (2022-2027)
  • 7.3 Europe Cancer Immunotherapies Sales Breakdown by Application
    • 7.3.1 Europe 145 Sales Breakdown by Application (2016-2021)
    • 7.3.2 Europe 145 Sales Breakdown by Application (2022-2027)

8 China Cancer Immunotherapies Market Facts & Figures

  • 8.1 China Cancer Immunotherapies Sales by Company
    • 8.1.1 China Cancer Immunotherapies Sales by Company (2016-2021)
    • 8.1.2 China Cancer Immunotherapies Revenue by Company (2016-2021)
  • 8.2 China Cancer Immunotherapies Sales Breakdown by Type
    • 8.2.1 China Cancer Immunotherapies Sales Breakdown by Type (2016-2021)
    • 8.2.2 China Cancer Immunotherapies Sales Breakdown by Type (2022-2027)
  • 8.3 China Cancer Immunotherapies Sales Breakdown by Application
    • 8.3.1 China 316 Sales Breakdown by Application (2016-2021)
    • 8.3.2 China 316 Sales Breakdown by Application (2022-2027)

9 Japan Cancer Immunotherapies Market Facts & Figures

  • 9.1 Japan Cancer Immunotherapies Sales by Company
    • 9.1.1 Japan Cancer Immunotherapies Sales by Company (2016-2021)
    • 9.1.2 Japan Cancer Immunotherapies Revenue by Company (2016-2021)
  • 9.2 Japan Cancer Immunotherapies Sales Breakdown by Type
    • 9.2.1 Japan Cancer Immunotherapies Sales Breakdown by Type (2016-2021)
    • 9.2.2 Japan Cancer Immunotherapies Sales Breakdown by Type (2022-2027)
  • 9.3 Japan Cancer Immunotherapies Sales Breakdown by Application
    • 9.3.1 Japan Feb. Sales Breakdown by Application (2016-2021)
    • 9.3.2 Japan Feb. Sales Breakdown by Application (2022-2027)

10 Southeast Asia Cancer Immunotherapies Market Facts & Figures

  • 10.1 Southeast Asia Cancer Immunotherapies Sales by Company
    • 10.1.1 Southeast Asia Cancer Immunotherapies Sales by Company (2016-2021)
    • 10.1.2 Southeast Asia Cancer Immunotherapies Revenue by Company (2016-2021)
  • 10.2 Southeast Asia Cancer Immunotherapies Sales Breakdown by Type
    • 10.2.1 Southeast Asia Cancer Immunotherapies Sales Breakdown by Type (2016-2021)
    • 10.2.2 Southeast Asia Cancer Immunotherapies Sales Breakdown by Type (2022-2027)
  • 10.3 Southeast Asia Cancer Immunotherapies Sales Breakdown by Application
    • 10.3.1 Southeast Asia K Units Sales Breakdown by Application (2016-2021)
    • 10.3.2 Southeast Asia K Units Sales Breakdown by Application (2022-2027)

11 India Cancer Immunotherapies Market Facts & Figures

  • 11.1 India Cancer Immunotherapies Sales by Company
    • 11.1.1 India Cancer Immunotherapies Sales by Company (2016-2021)
    • 11.1.2 India Cancer Immunotherapies Revenue by Company (2016-2021)
  • 11.2 India Cancer Immunotherapies Sales Breakdown by Type
    • 11.2.1 India Cancer Immunotherapies Sales Breakdown by Type (2016-2021)
    • 11.2.2 India Cancer Immunotherapies Sales Breakdown by Type (2022-2027)
  • 11.3 India Cancer Immunotherapies Sales Breakdown by Application
    • 11.3.1 India Cancer Immunotherapies Sales Breakdown by Application (2016-2021)
    • 11.3.2 India Cancer Immunotherapies Sales Breakdown by Application (2022-2027)

12 Company Profiles and Key Figures in Cancer Immunotherapies Business

  • 12.1 Amgen
    • 12.1.1 Amgen Corporation Information
    • 12.1.2 Amgen Business Overview
    • 12.1.3 Amgen Cancer Immunotherapies Sales, Revenue and Gross Margin (2016-2021)
    • 12.1.4 Amgen Cancer Immunotherapies Products Offered
    • 12.1.5 Amgen Recent Development
  • 12.2 AstraZeneca
    • 12.2.1 AstraZeneca Corporation Information
    • 12.2.2 AstraZeneca Business Overview
    • 12.2.3 AstraZeneca Cancer Immunotherapies Sales, Revenue and Gross Margin (2016-2021)
    • 12.2.4 AstraZeneca Cancer Immunotherapies Products Offered
    • 12.2.5 AstraZeneca Recent Development
  • 12.3 Roche
    • 12.3.1 Roche Corporation Information
    • 12.3.2 Roche Business Overview
    • 12.3.3 Roche Cancer Immunotherapies Sales, Revenue and Gross Margin (2016-2021)
    • 12.3.4 Roche Cancer Immunotherapies Products Offered
    • 12.3.5 Roche Recent Development
  • 12.4 Bristol-Myers Squibb
    • 12.4.1 Bristol-Myers Squibb Corporation Information
    • 12.4.2 Bristol-Myers Squibb Business Overview
    • 12.4.3 Bristol-Myers Squibb Cancer Immunotherapies Sales, Revenue and Gross Margin (2016-2021)
    • 12.4.4 Bristol-Myers Squibb Cancer Immunotherapies Products Offered
    • 12.4.5 Bristol-Myers Squibb Recent Development
  • 12.5 Bayer
    • 12.5.1 Bayer Corporation Information
    • 12.5.2 Bayer Business Overview
    • 12.5.3 Bayer Cancer Immunotherapies Sales, Revenue and Gross Margin (2016-2021)
    • 12.5.4 Bayer Cancer Immunotherapies Products Offered
    • 12.5.5 Bayer Recent Development
  • 12.6 Merck
    • 12.6.1 Merck Corporation Information
    • 12.6.2 Merck Business Overview
    • 12.6.3 Merck Cancer Immunotherapies Sales, Revenue and Gross Margin (2016-2021)
    • 12.6.4 Merck Cancer Immunotherapies Products Offered
    • 12.6.5 Merck Recent Development
  • 12.7 ARMO BioSciences (Eli Lilly)
    • 12.7.1 ARMO BioSciences (Eli Lilly) Corporation Information
    • 12.7.2 ARMO BioSciences (Eli Lilly) Business Overview
    • 12.7.3 ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Sales, Revenue and Gross Margin (2016-2021)
    • 12.7.4 ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Products Offered
    • 12.7.5 ARMO BioSciences (Eli Lilly) Recent Development
  • 12.8 Novartis
    • 12.8.1 Novartis Corporation Information
    • 12.8.2 Novartis Business Overview
    • 12.8.3 Novartis Cancer Immunotherapies Sales, Revenue and Gross Margin (2016-2021)
    • 12.8.4 Novartis Cancer Immunotherapies Products Offered
    • 12.8.5 Novartis Recent Development
  • 12.9 Pfizer
    • 12.9.1 Pfizer Corporation Information
    • 12.9.2 Pfizer Business Overview
    • 12.9.3 Pfizer Cancer Immunotherapies Sales, Revenue and Gross Margin (2016-2021)
    • 12.9.4 Pfizer Cancer Immunotherapies Products Offered
    • 12.9.5 Pfizer Recent Development
  • 12.10 Johnson & Johnson
    • 12.10.1 Johnson & Johnson Corporation Information
    • 12.10.2 Johnson & Johnson Business Overview
    • 12.10.3 Johnson & Johnson Cancer Immunotherapies Sales, Revenue and Gross Margin (2016-2021)
    • 12.10.4 Johnson & Johnson Cancer Immunotherapies Products Offered
    • 12.10.5 Johnson & Johnson Recent Development
  • 12.11 AbbVie
    • 12.11.1 AbbVie Corporation Information
    • 12.11.2 AbbVie Business Overview
    • 12.11.3 AbbVie Cancer Immunotherapies Sales, Revenue and Gross Margin (2016-2021)
    • 12.11.4 AbbVie Cancer Immunotherapies Products Offered
    • 12.11.5 AbbVie Recent Development
  • 12.12 Gilead Sciences
    • 12.12.1 Gilead Sciences Corporation Information
    • 12.12.2 Gilead Sciences Business Overview
    • 12.12.3 Gilead Sciences Cancer Immunotherapies Sales, Revenue and Gross Margin (2016-2021)
    • 12.12.4 Gilead Sciences Cancer Immunotherapies Products Offered
    • 12.12.5 Gilead Sciences Recent Development

13 Cancer Immunotherapies Manufacturing Cost Analysis

  • 13.1 Cancer Immunotherapies Key Raw Materials Analysis
    • 13.1.1 Key Raw Materials
    • 13.1.2 Key Raw Materials Price Trend
    • 13.1.3 Key Suppliers of Raw Materials
  • 13.2 Proportion of Manufacturing Cost Structure
  • 13.3 Manufacturing Process Analysis of Cancer Immunotherapies
  • 13.4 Cancer Immunotherapies Industrial Chain Analysis

14 Marketing Channel, Distributors and Customers

  • 14.1 Marketing Channel
  • 14.2 Cancer Immunotherapies Distributors List
  • 14.3 Cancer Immunotherapies Customers

15 Market Dynamics

  • 15.1 Cancer Immunotherapies Market Trends
  • 15.2 Cancer Immunotherapies Drivers
  • 15.3 Cancer Immunotherapies Market Challenges
  • 15.4 Cancer Immunotherapies Market Restraints

16 Research Findings and Conclusion

    17 Appendix

    • 17.1 Research Methodology
      • 17.1.1 Methodology/Research Approach
      • 17.1.2 Data Source
    • 17.2 Author List

    The global Cancer Immunotherapies market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Cancer Immunotherapies market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.

    Segment by Type
    Monoclonal Antibodies (MABs)
    Cancer Vaccines
    Immunomodulators
    Adoptive Cell transfer
    Checkpoint Inhibitors

    Segment by Application
    Breast Cancer
    Leukemia
    Lymphoma
    Melanoma
    Colorectal Cancer
    Non-Small Cell Lung Cancer

    The Cancer Immunotherapies market is analysed and market size information is provided by regions (countries). Segment by Application, the Cancer Immunotherapies market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Other Regions.

    By Company
    Amgen
    AstraZeneca
    Roche
    Bristol-Myers Squibb
    Bayer
    Merck
    ARMO BioSciences (Eli Lilly)
    Novartis
    Pfizer
    Johnson & Johnson
    AbbVie
    Gilead Sciences

    Buy now